Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
about
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
P2860
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Phase 1/2 study of lenalidomid ...... e-refractory multiple myeloma.
@ast
Phase 1/2 study of lenalidomid ...... e-refractory multiple myeloma.
@en
type
label
Phase 1/2 study of lenalidomid ...... e-refractory multiple myeloma.
@ast
Phase 1/2 study of lenalidomid ...... e-refractory multiple myeloma.
@en
prefLabel
Phase 1/2 study of lenalidomid ...... e-refractory multiple myeloma.
@ast
Phase 1/2 study of lenalidomid ...... e-refractory multiple myeloma.
@en
P2093
P1433
P1476
Phase 1/2 study of lenalidomid ...... e-refractory multiple myeloma.
@en
P2093
Aart Beeker
Andries C Bloem
Annemiek Broijl
Berris van Kessel
Dick-Johan van Spronsen
Ellen van der Spek
Gerard M J Bos
Harry R Koene
Henk M Lokhorst
Inger S Nijhof
P356
10.1182/BLOOD-2016-07-729236
P407
P577
2016-09-19T00:00:00Z